CD69 and neoplasm: As expected, the CD8+CD69+ T cells from PanNV plus αMSLN treated group exhibited nearly eight times of the tumor‐killing efficiency compared to those from the PBS and αMSLN treated groups, and nearly two times of the tumor‐killing efficiency compared to the PancNV treated group (p < 0.0001, Figure S6, Supporting Information).